IN8BIO, INC.
INABDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Autologous genetically modified gamma-delta T cells
Glioblastoma
INB-100
Acute Myeloid Leukemia (post haploidentical stem cell transplant)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Autologous genetically modified gamma-delta T cells | Phase 2 | Glioblastoma | - | - |
INB-100 | Phase 1 | Acute Myeloid Leukemia (post haploidentical stem cell transplant) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in IN8BIO, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in IN8BIO, INC.'s (INAB) pipeline across Phase 2, Phase 1. Its lead program is Autologous genetically modified gamma-delta T cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IN8BIO, INC.'s next FDA catalyst?→
IN8BIO, INC.'s (INAB) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INAB biotech catalysts?→
Add INAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IN8BIO, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.